97 related articles for article (PubMed ID: 2649005)
21. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
22. Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M
Leuk Res; 2004 May; 28(5):443-6. PubMed ID: 15068895
[No Abstract] [Full Text] [Related]
23. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
25. [Clinical effects of stearyl-ara-CMP (YNK-01) on chronic hematologic malignancies].
Im T; Ota K; Ohira H; Yasui Y; Nakao Y; Furukawa Y; Inoue K; Yamane T; Hiyoshi M; Kishida T
Gan To Kagaku Ryoho; 1991 Jan; 18(1):139-42. PubMed ID: 1987896
[No Abstract] [Full Text] [Related]
26. [Chemotherapy for chronic leukemia].
Kitajima K; Takahashi I; Fujimoto S
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1895-902. PubMed ID: 6964033
[TBL] [Abstract][Full Text] [Related]
27. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
28. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
29. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
32. [A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders].
Masaoka T; Oguma S; Shibata H; Nagai K; Horiuchi A; Kitani T; Yonezawa T; Kawagoe H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2793-9. PubMed ID: 3753025
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
[TBL] [Abstract][Full Text] [Related]
34. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow transplantation in leukemia.
Gale RP
Ann Clin Res; 1981; 13(4-5):367-72. PubMed ID: 7039488
[TBL] [Abstract][Full Text] [Related]
36. [Current aspects of therapy in chronic and acute leukemias].
Seipelt G; Hoelzer D
Schweiz Med Wochenschr; 1995 Jul; 125(27-28):1354-63. PubMed ID: 7624746
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy of haematological malignancies. Prognostic significance.
Klener P
Acta Univ Carol Med Monogr; 1979; 90():7-127. PubMed ID: 400423
[No Abstract] [Full Text] [Related]
39. [Principles of treatment of hemoblastoses under ambulatory conditions].
Polonskaia EN; Vinogradova IuE; Lobanova NA; Iudina NI; Korovina VI
Ter Arkh; 1976; 48(8):54-60. PubMed ID: 828780
[No Abstract] [Full Text] [Related]
40. [Drugs needed for treatment of patients with hemoblastosis].
Lebedev VN; Sarkisian SP
Probl Gematol Pereliv Krovi; 1977 Jun; 22(6):45-8. PubMed ID: 877053
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
